Home LiteratureArticle Details
PMID: 7867766 Published · ppublish English Journal Article

The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia.

Experimental neurology ·Vol. 130 ·No. 2 ·1994-12-00 ·Pages 362-7

Martin D, Chinookoswong N, Miller G

Abstract

We assessed the cerebral protective effects of the competitive interleukin-1 antagonist rhIL-1ra in 7-day-old rats that were subjected to brain hypoxia-ischemia by unilateral carotid artery ligation and subsequent exposure to 2 h of 7.5% O2-balanced N2. This procedure leads to atrophy in the cerebral hemisphere ipsilateral to carotid occlusion, with prominent foci of neuronal infarction in the striatum. Systemic administration of 100 mg/kg of rhIL-1ra before and/or after the hypoxic exposure limited the insult. The results indicate that rhIL-1ra has potent neuroprotective properties against morphologic brain injury from hypoxia-ischemia. rhIL-1ra may prove to be clinically useful in protecting against hypoxia-ischemia-related disorders.

MeSH Terms
Animals Brain Ischemia/pathology Cerebral Infarction/pathology Corpus Striatum/pathology Female Hypoxia/pathology Male Neuroprotective Agents/pharmacology Rats Rats, Sprague-Dawley Receptors, Interleukin-1/antagonists & inhibitors Recombinant Proteins
Chemicals
Neuroprotective Agents Receptors, Interleukin-1 Recombinant Proteins
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Martin D
Department of Pharmacology, Synergen, Inc., Boulder, Colorado 80301.
Chinookoswong N
Miller G
Article Info
Journal
Experimental neurology
Abbr.
Exp Neurol
ISSN
0014-4886
Published
1994-12-00
Pages
362-7
Language
English
Region
United States
NLM ID
0370712
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]